Ethris has partnered with contract development and manufacturing organisation Lonza for the development of room-temperature ...

Ethris, a clinical-stage biotechnology company creating RNA therapeutics and vaccines, and Lonza entered a collaboration to develop room-temperature stable, spray-dried formulations of mRNA-based ...

Ethris and Lonza collaborate to develop spray-dried mRNA vaccines for respiratory disease prevention: Munich, Germany Wednesday, April 9, 2025, 13:00 Hrs [IST] Ethris, a clinical- ...

Ethris and Lonza agreed to collaborate on the development of room-temperature stable, spray-dried formulations of mRNA-based vaccine candidates, designed for mucosal delivery to combat respiratory ...

Under the terms of the agreement, Lonza will provide spray-drying and particle engineering for vaccine candidates based on Ethris’ stabilized non-immunogenic mRNA (SNIM® RNA) and stabilized ...

AstraZeneca and its biologics research arm MedImmune have signed a five-year strategic research collaboration with Ethris, an mRNA-based therapeutics company specialising in pulmonary disease.

Samina Hamied, 48, third generation heir to Cipla, founded in 1935 by her grandfather Khwaja Abdul Hamied, challenges herself ...

Credit: mi_viri/Shutterstock. Ethris has partnered with contract development and manufacturing organisation Lonza for the development of room-temperature stable mRNA vaccine candidates targeting ...